YUTREPIA™ (treprostinil) — Full data
2026
Completing the ASCENT open-label study evaluating 52 weeks of treatment in PH-ILD patientsSource filing
LQDA biotech catalysts & pipeline
LIQUIDIA CORP · Data as of 2026-10-25
catalyst calendar
/
catalyst calendar
LIQUIDIA CORP · Data as of 2026-10-25
2026
Completing the ASCENT open-label study evaluating 52 weeks of treatment in PH-ILD patientsSource filing